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OBJECTIVE — Mortality rates have declined substantially over the past decades in the gen-
eral population, but the situation among diabetic subjects is less clear. The aim of this study was
to analyze mortality trends in diabetic and nondiabetic subjects during 1972–2004.
RESEARCH DESIGN AND METHODS — Since 1972, all patients with diabetes are
entered in a diabetes register at Laxå Primary Health Care Center; 776 incident cases were
recorded up to 2001. The register has been supplemented with a nondiabetic population of
3,880 subjects and with data from the National Cause of Death Register during 1972 to 2004.
RESULTS — During the 33-year follow-up period, 233 (62.0%) diabetic women and 240
(60.0%)diabeticmenand995(52.9%)nondiabeticwomenand1,082(54.1%)nondiabeticmen
died.Theage-adjustedhazardratio(HR)forall-causemortalityamongdiabeticandnondiabetic
subjects was 1.17 (P  0.0021) for all, 1.22 (P  0.007) for women, and 1.13 (P  0.095) for
men. The corresponding cardiovascular disease (CVD) mortality HRs were 1.33 (P  0.0001),
1.41 (P  0.0003), and 1.27 (P  0.0093), respectively. The CVD mortality reduction across
time was signiﬁcant in nondiabetic subjects (P  0.0001) and in men with diabetes (P  0.014)
but not in diabetic women (P  0.69). The results regarding coronary heart disease (CHD) were
similar (P  0.0001, P  0.006, and P  0.17, respectively). The CVD and CHD mortality rate
change across time was fairly linear in all groups.
CONCLUSIONS — Diabetic subjects had less mortality rate reduction during follow-up
than nondiabetic subjects. However the excess mortality risk for diabetic subjects was smaller
than that found in other studies.
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T
heexcessmortality,mostlyowingto
cardiovascular disease (CVD), in di-
abetic subjects compared with non-
diabetic subjects, is well documented
(1–4)andhasbeenshowntodeclinewith
increasing age at diagnosis (1,3,5). How-
ever, studies of the inﬂuence of sex on
mortality risk for those with and without
diabetes show conﬂicting results (1,6,7).
CVD incidence and mortality rates
have declined in most developed coun-
tries, including Sweden, over the past de-
cades (8–10). Because CVD is the major
cause of death among diabetic and non-
diabetic subjects, it would be expected
that the general decline in mortality
would be reﬂected in both groups. Data
from Framingham reported parallel de-
clines in CVD outcomes for diabetic and
nondiabetic women and men between
1950 and 1995 (11). Another U.S. study
(12)conﬁrmedamortalitydeclineduring
1971 to 2000 for diabetic men but not
women, whereas a Canadian study (13)
showed reduced mortality rates for both
sexes during 1995 to 2005. A Danish
study (14) reported a faster reduction in
mortality in diabetic subjects than in a
nondiabetic population between 1995
and 2006, and a Norwegian study (15)
showed a substantial decrease in mortal-
ity from coronary heart disease (CHD) for
both diabetic and nondiabetic subjects
and for both sexes from the mid-1980s to
the mid-1990s. A Swedish study (16)
covering the period 1980–2004 showed
improved survival rates in diabetic sub-
jects, more so in diabetic women than in
men, thereby narrowing the gap to non-
diabetic women.
The aim of this study was to analyze
mortalitytrendsamongdiabeticandnon-
diabetic subjects over the time period
1972–2004inadeﬁnedgeographicalarea
in Sweden and to test the hypothesis that
changes in all-cause, CVD, and CHD
mortality have been parallel among the
two cohorts.
RESEARCH DESIGN AND
METHODS
Diabetic subjects
The study was undertaken in Laxå, O ¨ re-
bro County, Sweden. From 1 January
1972 and onward all new cases of diabe-
tes among residents in Laxå were entered
into a diabetes register at Laxå Primary
Health Care Center (PHCC). Patient
record ﬁles at the local PHCC, at nearby
PHCCs, at private practitioners’ ofﬁces,
andatadjacenthospitalsandprescription
registers at the local pharmacies were
scrutinized to ﬁnd possible missing cases,
as described in detail previously (17).
During1972to2001,altogether776new
cases of diabetes were found, 36 type 1
and 740 type 2 diabetes.
Nondiabetic subjects
For each new diabetic subject, ﬁve (max-
imum number available) nondiabetic
subjects were sampled in 2007 from
the Laxå general population register,
matched to the diabetic subjects by sex
and age, sampled from the population
register version of the diagnosis year, and
required to not have a diabetes diagnosis
atanytimefrombaselinetoendoffollow-
up. Several diabetes screening rounds
during the study period were used to
eliminate misclassiﬁcation. No clinical
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hort. Altogether 3,880 subjects, 1,880
women and 2,000 men, were sampled.
Death ascertainment
Mortalitydatauntil2004forthecomplete
study population were obtained from the
National Cause of Death Registry. Data
obtained included date and place of
death,underlyingcauseofdeathandcon-
tributing causes of death. The causes of
deathwerecodedaccordingtotheICD-8,
ICD-9, and ICD-10. The Regional Re-
search Ethics Board in Uppsala, Sweden,
approved the study.
Statistical considerations
ThedatawereanalyzedusingSAS(release
9.1, SAS Institute, Cary, NC). Simple dif-
ferences between groups were tested with
Student’s t test, variance analysis, or the

2 test.
Survival analyses were performed
with Cox’s proportional hazards regres-
sion,modeledwiththeoutcomeandtime
as the dependent variables and age, dia-
betes status, and year of diagnosis and in-
clusion to the study as independent
variables and stratiﬁed for sex. In addi-
tion, two interaction terms, diabetes sta-
tus-year of diagnosis and diabetes status-
year of diagnosis-sex, were tested. The
former was signiﬁcant for some out-
comes, which was used for further
modeling.
For illustration purposes some of the
results are shown for the three periods
1972–1981, 1982–1991, and 1992–
2001, all based on the time of diabetes
diagnosis. The follow-up time was right-
truncated at 26, 20, and 10 years for the
three partial study periods owing to small
numbers.
Finally, to allow equal exposure
times when mortality rate per year of
diagnosis was analyzed, 3-year follow
Table 1—Baseline characteristics among diabetic women and men
Women Men
Decade 1:
1972–1981
Decade 2:
1982–1991
Decade 3:
1992–2001
Decade 1:
1972–1981
Decade 2:
1982–1991
Decade 3:
1992–2001
n 131 140 105 133 154 113
Age at diagnosis (years) 65.0  15.3 66.1  13.4 62.1  15.1 62.6  14.1 61.2  17.1 58.4  14.6
FBG (mmol/l) 9.6  2.8 8.3  2.3 7.4  2.2* 9.1  2.6 9.1  12.4 8.6  3.6
BMI (kg/m
2) 30.2  6.1 29.7  6.0 31.2  5.6 28.8  3.4 28.0  4.5 30.6  4.8*
Smokers (%) 3.8 7.9 14.3† 12.0 15.6 18.6
Ex-smokers (%) 3.1 5.0 7.6 8.3 20.1 31.0*
AHD (%) 51.9 63.6 53.3‡ 51.9 50.0 38.0
Diabetes treatment during the ﬁrst year
Diet only (%) 67.9 77.9 76.2† 63.2 71.4 82.3*
OHA (%) 29.8 16.4 15.2† 32.3 20.1 8.8*
OHA and insulin (%) 2.3 0.0 0.0 3.0 0.6 3.5
Insulin (%) 0.0 5.7 8.6 1.5 7.8 5.3
Data are means  SD or %. *P  0.001; †P  0.01; ‡P  0.05. AHD, antihypertensive drug; FBG, fasting blood glucose; OHA, oral hypoglycemic agent.
Table 2—Mortality during follow-up 1972–2004 among diabetic and nondiabetic subjects
Diabetes No diabetes
Ratio diabetic and nondiabetic
women
Ratio diabetic and nondiabetic
men
Women Men Women Men HR (95% CI) P HR (95% CI) P
CVD 141 (37.6) 147 (36.7) 523 (27.8) 587 (29.3) 1.41 (1.17–1.70) 0.0003 1.27 (1.06–1.52) 0.0093
CHD 80 (21.3) 103 (25.8) 274 (14.6) 385 (19.3) 1.50 (1.17–1.92) 0.0015 1.35 (1.08–1.68) 0.0072
Cerebrovascular
disease 33 (8.8) 28 (7.0) 130 (6.9) 97 (4.8) 1.39 (0.94–2.04) NS 1.49 (0.98–2.27) NS
Other CVD 28 (7.5) 16 (4.0) 119 (6.3) 105 (5.2) 1.22 (0.81–1.84) NS 0.78 (0.46–1.33) NS
Malignant neoplasms 32 (8.5) 41 (10.2) 211 (11.2) 241 (12.0) 0.76 (0.53–1.11) NS 0.87 (0.63–1.22) NS
Respiratory disease 14 (3.7) 11 (2.8) 62 (3.3) 65 (3.2) 1.21 (0.68–2.16) NS 0.85 (0.45–1.61) NS
Endocrine disease 14 (3.7) 12 (3.0) 13 (0.7) 11 (0.5) 5.53 (2.59–11.81) 0.0001 5.89 (2.59–13.40) 0.0001
Digestive disease 11 (2.9) 9 (2.2) 42 (2.2) 40 (2.0) 1.37 (0.70–2.67) NS 1.14 (0.55–2.34) NS
Injury 6 (1.6) 5 (1.2) 33 (1.7) 53 (2.7) 0.91 (0.38–2.18) NS 0.46 (0.19–1.16) NS
MB disorder 5 (1.3) 0 23 (1.2) 13 (0.7) 1.46 (0.55–3.91) NS — —
Infectious disease 3 (0.8) 3 (0.8) 13 (0.7) 14 (0.7) 1.24 (0.35–4.36) NS 1.05 (0.30–3.64) NS
GU disease 3 (0.8) 7 (1.8) 18 (1.0) 23 (1.2) 0.90 (0.26–3.06) NS 1.62 (0.69–3.79) NS
Nervous disease 1 (0.3) 1 (0.3) 20 (1.1) 13 (0.7) 0.26 (0.03–1.90) NS 0.38 (0.05–2.94) NS
All other diseases 3 (0.8) 4 (1.0) 37 (2.0) 22 (1.1) 0.44 (0.13–1.41) NS 0.93 (0.32–2.70) NS
All causes 233 (62.0) 240 (60.0) 995 (52.9) 1,082 (54.1) 1.22 (1.06–1.40) 0.0071 1.13 (0.98–1.30) NS
Data are n (%) or HR (95% CI). Ratios between diabetic and nondiabetic subjects were adjusted for the inﬂuence of age, sex, and calendar year. GU, genitourinary
disease; MB, mental and behavioral disorder.
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study in 2001 only had 3 years of fol-
low-up. P  5% was regarded as statis-
tically signiﬁcant.
RESULTS
Characteristics of the study
population
Mean  SD age at diagnosis for diabetic
subjects and fasting blood glucose de-
creased over the three decades, whereas
BMI and the proportion of smokers and
former smokers increased, as did the pro-
portion of subjects using diet only as dia-
betes treatment (Table 1).
Trends in all-cause mortality
During the 33-year follow up period, 233
(62.0%) diabetic women and 240
(60.0%) diabetic men and 995 (52.9%)
nondiabetic women and 1,082 (54.1%)
nondiabeticmendied(Table2).Age-and
sex-adjusted hazard ratios (HRs) for all-
cause mortality during 1972 to 2004 in
diabetic and nondiabetic subjects were
1.17 (P  0.0021) for the total sample
(data not shown), 1.22 (P  0.007) for
women, and 1.13 (P  0.095) for men.
Cumulativemortalityratesduringthe
whole follow-up period in the three de-
cades are shown in Fig. 1A–F. Mortality
decreased in nondiabetic subjects of both
sexes (P  0.0001). For diabetic men
there was a similar tendency (P  0.045),
whereas no such development could be
seen for diabetic women (P  0.72). The
mortality trends during the follow-up pe-
riod in relation to age and year of diagno-
sis for diabetic and nondiabetic subjects
are shown in Table 3. For both cohorts
and for both sexes the all-cause mortality
risk (HR) increased by age (P  0.0001).
The nondiabetic subjects had a decreased
mortality rate over time by almost 30%
per10years.Diabeticsubjectshadnosig-
niﬁcant change over time, although there
was a tendency toward a decrease among
menwithdiabetes.Nosigniﬁcantinterac-
tions between time period and diabetes
status for all-cause mortality were found.
Figure 1—Cumulative mortality among diabetic and nondiabetic women and men during three time periods. A: Exposed diabetic (n  131) and
nondiabetic women (n  655) 1972–1981. B: Exposed diabetic (n  140) and nondiabetic women (n  700) 1982–1991. C: Exposed diabetic
(n  105) and nondiabetic women (n  525) 1992–2001. D: Exposed diabetic (n  133) and nondiabetic men (n  665) 1972–1981. E: Exposed
diabetic (n  154) and nondiabetic men (n  770) 1982–1991. F: Exposed diabetic (n  113) and nondiabetic men (n  565) 1992–2001.
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were performed, a statistically signiﬁcant
interactionwasfoundfordiabeticwomen
(P0.004)butnotfordiabeticmen(P
0.15).
Trends in CVD and CHD mortality
The age- and sex-adjusted CVD and CHD
mortality rates were signiﬁcantly higher
for diabetic than for nondiabetic subjects:
CVDmortalityHR1.33(P0.0001)and
CHD mortality HR 1.41 (P  0.0001)
(data not shown). Both diabetic women
and men had signiﬁcantly higher risk
than nondiabetic subjects of dying from
CVD and within this group of disease
from CHD but not from other cardiovas-
cular causes (Table 2). The associations
between age and CVD mortality trends
were similar to the associations between
age and all-cause mortality (Table 3). Di-
abetic and nondiabetic men had a similar
average decrease over calendar time,
whereas diabetic women had no such
change(nondiabeticsubjectsP0.0001,
diabetic men P  0.014, and diabetic
women P  0.69). For CHD mortality,
the associations were similar for both age
and diagnosis year to those for CVD mor-
tality (nondiabetic subjects P  0.0001,
diabetic men P  0.006), and diabetic
women P  0.17). No signiﬁcant interac-
tions between time period and diabetes
status for CVD and CHD mortality were
found (P  0.10).
Trends in non-CVD mortality
As expected, the mortality risk was signif-
icantly increased for endocrine disease
among diabetic subjects. For all other
causes, there were no signiﬁcant differ-
ences(Table2).Apronouncedincreasein
mortality risk by age was seen for diabetic
and nondiabetic subjects for cerebrovas-
cular disease. No signiﬁcant associations
of diagnosis year, either among diabetic
subjects or among nondiabetic subjects,
were detected. There was a signiﬁcantly
increased HR for malignant neoplasm
mortality and mortality from all other
causesbyagefordiabeticandnondiabetic
subjects of both sexes, but only nondia-
beticsubjectshadasigniﬁcantdecreasein
HR with calendar time (Table 3). There
wasasigniﬁcantinteractionbetweentime
period and diabetes status for malignant
neoplasmmortality(P0.02)butnotfor
mortality from all other causes (P 
0.10).
Trends across time
A more detailed analysis of the time se-
quence in the course of events was made
onthebasisofyearofinclusionofdiabetic
andnondiabeticsubjectsandwith3years
offollow-up.Thecourseofeventsregard-
ing CVD and CHD mortality is shown in
Fig. 2A–D. Generally, the mortality rates
fell gradually by year of inclusion, but
faster among nondiabetic than diabetic
subjects.
CONCLUSIONS — The excess mor-
talityriskfordiabeticthanfornondiabetic
subjects was low in our study and espe-
cially so for men. Nondiabetic but not
diabetic subjects had signiﬁcantly im-
proved survival during the study period.
However, diabetic men had substantially
lower CVD mortality, particularly CHD
mortality, during the third compared
with the previous decades, whereas dia-
betic women had a slower rate of im-
provement. The improved survival for
nondiabetic subjects was due to reduced
mortality from CVD, malignant disease,
and all other causes. Diabetic subjects
showed no such improvement over the
study period. Together with the un-
changed CVD mortality, this constituted
the basis of the lack of improvement of
survival for the diabetic subjects. How-
ever, an interesting and promising ﬁnd-
ing was that diabetic men had as good
an improvement in survival as nondia-
betic men regarding CVD and CHD
Table 3—Associations between age and diagnosis year on mortality from all causes, CVDs, and malignant diseases among diabetic and
nondiabetic subjects
Diabetes No diabetes
Women Men Women Men
HR (95% CI) 
2 HR (95% CI) 
2 HR (95% CI) 
2 HR (95% CI) 
2
Mortality, all causes
Age, 10-year groups 2.42 (2.07–2.82) 125.3 2.20 (1.93–2.51) 137.1 2.47 (2.31–2.66) 629.6 2.31 (2.18–2.46) 705.7
Diagnosis year, by 10 years 1.02 (0.84–1.24) 0.04 0.83 (0.68–1.01) 3.5 0.71 (0.65–0.78) 48.5 0.72 (0.66–0.79) 51.5
CVD mortality
Age, 10-year groups 2.45 (2.00–2.99) 76.8 2.22 (1.87–2.63) 84.9 3.08 (2.78–3.41) 455.0 2.61 (2.39–2.84) 463.9
Diagnosis year, by 10 years 0.95 (0.74–1.22) 0.2 0.73 (0.57–0.94) 6.0 0.70 (0.62–0.80) 26.9 0.69 (0.61–0.78) 37.0
CHD mortality
Age, 10-year groups 2.09 (1.63–2.69) 33.5 2.06 (1.69–2.52) 51.3 2.97 (2.58–3.41) 230.1 2.43 (2.19–2.70) 273.7
Diagnosis year, by 10 years 0.79 (0.56–1.11) 1.9 0.65 (0.48–0.88) 7.6 0.59 (0.49–0.71) 31.8 0.63 (0.54–0.73) 38.0
Cerebrovascular disease
mortality
Age, 10-year groups 3.44 (2.17–5.46) 27.7 2.70 (1.81–4.10) 23.3 3.23 (2.61–3.98) 118.4 3.16 (2.52–3.97) 99.0
Diagnosis year, by 10 years 1.24 (0.73–2.09) 0.6 0.98 (0.53–1.78) 0 0.77 (0.58–1.01) 3.5 0.76 (0.56–1.03) 3.0
Malignant neoplasm mortality
Age, 10-year groups 1.43 (1.04–1.97) 4.8 1.93 (1.43–2.60) 18.5 1.61 (1.42–1.83) 52.2 1.85 (1.64–2.10) 99.3
Diagnosis year, by 10 years 1.37 (0.83–2.24) 1.5 1.27 (0.80–2.03) 1.0 0.68 (0.56–0.83) 14.6 0.72 (0.59–0.88) 10.8
Mortality from all other causes
Age, 10-year groups 3.59 (2.52–5.11) 49.9 2.39 (1.78–3.19) 34.3 2.47 (2.15–2.84) 164.7 2.22 (1.96–2.52) 154.8
Diagnosis year, by 10 years 1.01 (0.67–1.53) 0.002 0.84 (0.54–1.30) 0.6 0.77 (0.63–0.93) 7.5 0.81 (0.67–0.97) 5.3
Data are HRs (95% CI) or 
2 estimate.
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women, although a positive tendency
was seen (Table 3).
ThereducedCVDandCHDmortality
among men but not among women with
diabetes, was similar to what others have
found (12,18). On the other hand, other
studies showed the opposite, a higher
mortality rate among men (2,7), and still
others found no sex differences (11,15).
The lack of improvement among women
in our study may have several explana-
tions ranging from sex differences in care
provision and/or care adherence, to the
diabetes disease itself, which has been
claimedtohaveagreateradverseaffecton
CVD risk factors in women than in men
(19).
Several factors may explain the de-
crease in mortality among nondiabetic
subjects over the last decades. These
include successful primary prevention
of CVD risk factors such as smoking,
improved lipid and blood pressure
treatments, and accompanying lifestyle
changes in addition to improvements in
life-saving technologies for those devel-
oping acute CHD over the years.
All of these improvements in CVD
mortality in the nondiabetic population
may also be seen in the diabetic popula-
tion, but they occur later and are not of
the same order of magnitude and diabetic
women lag behind diabetic men. Some
possibleexplanationsforthisunfavorable
development might be that diabetic sub-
jectsaresmokersandoverweightorobese
to a larger extent than nondiabetic sub-
jects and do not reach the treatment goals
for blood pressure, lipids, and A1C ac-
cording to the guidelines (20). A further
negative circumstance for diabetic com-
pared with nondiabetic subjects and es-
pecially so for diabetic women is their
worseprognosisafteranacutemyocardial
infarction (21).
Goodscientiﬁcevidenceabouttheef-
fects of treatment of hyperglycemia, high
blood pressure and dyslipidemia came
fairly late in our study with the UK
Prospective Diabetes Study (UKPDS)
(22,23).TheUKPDSwasfollowedbysev-
eral other reports: one meta-analysis
showingtheadvantagesoftreatinghyper-
cholesterolemia (24) and another focus-
ing on multifactorial intervention (25). It
will take some time before these ﬁndings
are implemented in clinical practice
widely enough to have an impact on the
health and survival of diabetic subjects.
When interpreting the improvements
in CVD mortality among diabetic sub-
jects, one should keep in mind the case-
ﬁnding strategies started in 1983. A
possible lead time bias introduced by
these strategies might have affected the
three diabetes cohorts differently. Sub-
jects with diabetes diagnosed in the last
compared with the ﬁrst decade were
younger and had lower fasting blood glu-
cose, indicating a more favorable progno-
sis.However,takingtheinﬂuenceofthese
factors into account in the analyses did
not affect the result.
The strengths of this study include
the fact that all incident diabetic subjects
in a deﬁned geographical area were iden-
tiﬁed using uniform diagnostic criteria
and followed over a long time period. All
Swedish residents have a unique 12-digit
personal identiﬁcation number, which is
an excellent and highly reliable tool for
record linkage. Patient fees for hospital
outpatient and general practice appoint-
Figure 2—Proportion (%) not dead from CVD and CHD across the total study period among diabetic and nondiabetic women and men. A: CVD
mortalityamongdiabeticandnondiabeticwomen1972–2001.B:CVDmortalityamongdiabeticandnondiabeticmen1972–2001.C:CHDmortality
among diabetic and nondiabetic women 1972–2001. D: CHD mortality among diabetic and nondiabetic men 1972–2001.
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and local governments, which means that
private ﬁnancial resources are seldom an
obstacle to health care utilization. These
factors,togetherwithexcellentcontinuity
in the diabetes care given, may be one
explanation for the low excess mortality
risk seen in our study compared with
what others have found (6,7,11,15).
Moreover, the absence of known dia-
betes in the reference group makes the
risk estimates in our study a forceful rep-
resentation of the true risk. Furthermore,
in our study, as opposed to many other
studies, all incident diabetic subjects re-
gardless of age were included. The mor-
tality data were based on the ofﬁcial
Cause of Death Register and were 100%
complete.
The limitations of the study include
the fairly small study area with an ethni-
cally homogeneous Caucasian popula-
tion. As a result, generalizations to
ethnicallydifferentpopulationsshouldbe
made cautiously. Furthermore, nondia-
betic subjects sampled for the period
1972–1982whodiedbeforetheopportu-
nistic case ﬁnding procedures started in
1983 may have included some subjects
with undiagnosed diabetes, causing a di-
lution of the mortality comparisons for
this period.
Insummary,thenovelﬁndingsinthis
study were the low excess mortality risk
for diabetic than for nondiabetic subjects.
Nondiabeticbutnotdiabeticsubjectshad
a signiﬁcant all-cause, CVD, and CHD
mortality reduction during the 33-year
follow-up whereas diabetic men but not
women had a signiﬁcant average reduc-
tionofCVDandespeciallyCHDmortality
rates.
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